<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05121610</url>
  </required_header>
  <id_info>
    <org_study_id>EDGE</org_study_id>
    <nct_id>NCT05121610</nct_id>
  </id_info>
  <brief_title>Effects of Different Revascularization StrateGies in Complex Coronary Artery DiseasE (EDGE)</brief_title>
  <official_title>Effects of Different Revascularization Strategies on Cardiovascular Outcomes in Patients With Complex Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary heart disease is one of the most serious diseases that endanger people's health.&#xD;
      Complex coronary artery disease is critical and has high mortality. Therefore, it is urgent&#xD;
      to explore the best treatment method for complex coronary artery disease. Some previous&#xD;
      studies have shown that patients with left main coronary artery disease with a SYNTAX score&gt;&#xD;
      32 points, and diabetic/non-diabetic three-vessel disease patients with coronary heart&#xD;
      disease with a SYNTAX score &gt; 22 points, CABG is recommended for revascularization. However,&#xD;
      with the continuous innovation of surgical technology and the rapid development of surgical&#xD;
      instruments, the treatment of patients with complex coronary artery disease is increasing.&#xD;
      Therefore, it is necessary to investigate the effects of different revascularization&#xD;
      strategies on long-term prognosis in patients with complex coronary artery disease (SYNTAX&#xD;
      score &gt; 22 points).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>Major adverse cardiovascular and cerebrovascular events (MACCE) at 1 year, including all-cause death, non-fatal myocardial infarction, ischemia-driven revascularization, and non-fatal stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause death is defined as death from cardiovascular causes, death from non-cardiovascular causes, and death from unknown causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>Non-fatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Ischemia-driven revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal stroke</measure>
    <time_frame>1 year</time_frame>
    <description>Stroke is defined as a neurological deficit with symptoms or signs that last at least 24 hours and imaging studies (CT or MRI) confirm the presence of cerebral infarction or cerebral hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite endpoints including all-cause death, non-fatal myocardial infarction, and ischemia-driven revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>The composite endpoints including all-cause death, non-fatal myocardial infarction, and ischemia-driven revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite endpoints including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke</measure>
    <time_frame>1 year</time_frame>
    <description>The composite endpoints including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite endpoints including cardiovascular death or nonfatal myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>The composite endpoints including cardiovascular death or nonfatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All bleeding events defined by the BARC bleeding criteria</measure>
    <time_frame>1 year</time_frame>
    <description>All bleeding events defined by the BARC bleeding criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 2, 3 and 5 bleeding events defined by the BARC bleeding criteria</measure>
    <time_frame>1 year</time_frame>
    <description>Type 2, 3 and 5 bleeding events defined by the BARC bleeding criteria</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2864</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CABG group</arm_group_label>
    <description>CABG group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCR group</arm_group_label>
    <description>HCR group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCI group</arm_group_label>
    <description>PCI group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>The procedures include PCI, CABG and HCR</intervention_name>
    <description>The procedures include PCI, CABG and HCR</description>
    <arm_group_label>CABG group</arm_group_label>
    <arm_group_label>HCR group</arm_group_label>
    <arm_group_label>PCI group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with complex coronary artery disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/female aged 18-80 years;&#xD;
&#xD;
          2. Having complex coronary artery disease (SYNTAX score &gt; 22 points) undergoing&#xD;
             myocardial revascularization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiogenic shock or hemodynamic instability;&#xD;
&#xD;
          2. Undergoing other heart surgery at the same time;&#xD;
&#xD;
          3. Previous coronary artery bypass surgery;&#xD;
&#xD;
          4. History of cerebral hemorrhage;&#xD;
&#xD;
          5. Ischemic stroke in the past six months;&#xD;
&#xD;
          6. History of cancer;&#xD;
&#xD;
          7. Life expectancy no more than 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongmei Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miao Yu, Doctor</last_name>
    <phone>13811879285</phone>
    <email>evelynym@hotmail.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Yujie Zhou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>CABG</keyword>
  <keyword>HCR</keyword>
  <keyword>Complex coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

